DE69123123T2 - Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen - Google Patents

Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen

Info

Publication number
DE69123123T2
DE69123123T2 DE69123123T DE69123123T DE69123123T2 DE 69123123 T2 DE69123123 T2 DE 69123123T2 DE 69123123 T DE69123123 T DE 69123123T DE 69123123 T DE69123123 T DE 69123123T DE 69123123 T2 DE69123123 T2 DE 69123123T2
Authority
DE
Germany
Prior art keywords
ylmethyl
methylbenzenesulfonamide
methoxybenzoyl
methylindol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69123123T
Other languages
German (de)
English (en)
Other versions
DE69123123D1 (de
Inventor
Martin Paul Edwards
John David Sherwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE69123123D1 publication Critical patent/DE69123123D1/de
Application granted granted Critical
Publication of DE69123123T2 publication Critical patent/DE69123123T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69123123T 1990-12-12 1991-12-11 Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen Expired - Lifetime DE69123123T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
DE69123123D1 DE69123123D1 (de) 1996-12-19
DE69123123T2 true DE69123123T2 (de) 1997-03-06

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123123T Expired - Lifetime DE69123123T2 (de) 1990-12-12 1991-12-11 Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen

Country Status (28)

Country Link
US (1) US5294636A (enExample)
EP (1) EP0490649B1 (enExample)
JP (1) JP2650807B2 (enExample)
KR (1) KR100194479B1 (enExample)
CN (2) CN1032469C (enExample)
AP (1) AP286A (enExample)
AT (1) ATE145199T1 (enExample)
AU (1) AU656344B2 (enExample)
CA (1) CA2056067C (enExample)
CZ (1) CZ288151B6 (enExample)
DE (1) DE69123123T2 (enExample)
DK (1) DK0490649T3 (enExample)
ES (1) ES2094797T3 (enExample)
FI (1) FI101296B1 (enExample)
GB (2) GB9027018D0 (enExample)
GR (1) GR3021605T3 (enExample)
HK (1) HK81497A (enExample)
HU (2) HU213109B (enExample)
IE (1) IE914316A1 (enExample)
IL (1) IL100090A (enExample)
MX (1) MX9102475A (enExample)
MY (1) MY108629A (enExample)
NZ (1) NZ240940A (enExample)
PH (1) PH30041A (enExample)
RU (1) RU2107682C1 (enExample)
SK (1) SK279018B6 (enExample)
TW (1) TW222264B (enExample)
ZA (1) ZA919772B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0455596T3 (da) * 1990-05-04 1994-11-28 Ciba Geigy Ag Substituerede indoler
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3732508B2 (ja) * 1993-10-01 2006-01-05 アストラ・アクチエボラーグ 粉末状薬剤の製造方法
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CA3052071A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
JP2024521736A (ja) 2021-05-19 2024-06-04 クエルシス ファーマ エージー 筋萎縮性側索硬化症の治療に使用するためのケルセチン含有組成物
US20250275936A1 (en) 2022-05-06 2025-09-04 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
TW222264B (enExample) 1994-04-11
PH30041A (en) 1996-11-08
GB9126353D0 (en) 1992-02-12
SK279018B6 (sk) 1998-05-06
AU656344B2 (en) 1995-02-02
KR100194479B1 (ko) 1999-06-15
AU8899591A (en) 1992-06-18
NZ240940A (en) 1994-05-26
GR3021605T3 (en) 1997-02-28
CA2056067C (en) 2001-09-04
IL100090A (en) 1996-09-12
US5294636A (en) 1994-03-15
DE69123123D1 (de) 1996-12-19
MY108629A (en) 1996-10-31
ATE145199T1 (de) 1996-11-15
JP2650807B2 (ja) 1997-09-10
HU211125A9 (en) 1995-10-30
GB9027018D0 (en) 1991-01-30
CN1063100A (zh) 1992-07-29
CN1074411C (zh) 2001-11-07
DK0490649T3 (da) 1997-04-21
ES2094797T3 (es) 1997-02-01
KR920012031A (ko) 1992-07-25
HU913863D0 (en) 1992-02-28
IE914316A1 (en) 1992-06-17
FI915825L (fi) 1992-06-13
FI101296B (fi) 1998-05-29
GB2250743B (en) 1995-02-15
CZ288151B6 (en) 2001-05-16
MX9102475A (es) 1992-06-01
CN1032469C (zh) 1996-08-07
CA2056067A1 (en) 1992-06-13
AP9100341A0 (en) 1992-01-31
JPH04266872A (ja) 1992-09-22
FI915825A0 (fi) 1991-12-11
HK81497A (en) 1997-06-27
CN1148491A (zh) 1997-04-30
GB2250743A (en) 1992-06-17
HUT60717A (en) 1992-10-28
RU2107682C1 (ru) 1998-03-27
AP286A (en) 1993-09-26
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
EP0490649B1 (en) 1996-11-13
EP0490649A1 (en) 1992-06-17
ZA919772B (en) 1992-09-30
HU213109B (en) 1997-02-28
FI101296B1 (fi) 1998-05-29

Similar Documents

Publication Publication Date Title
DE69123123T2 (de) Eine physikalische Form von N-[4-[5-(Cyclopentyloxycarbonylamino)-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl]-2-methylbenzolsulfonamid, ein Verfahren zu dessen Herstellung und es enthaltende pharmazeutische Zusammensetzungen
DE69115229T2 (de) Arzneimittel.
EP1326862B1 (de) Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE69217762T2 (de) Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
EP0017778B1 (de) Verfahren zur Herstellung eines wasserfreien, rieselfähigen, kristallinen, Fruktose enthaltenden Materials
EP0212537B1 (de) Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid
DE19546249A1 (de) Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE3784260T2 (de) Verbesserte spruehgetrocknete lactose und verfahren zu deren herstellung.
DE69125803T2 (de) Melassehaltiges maltitolkristall und herstellung desselben
DE60131416T2 (de) Chirale fluochinolon-argininsalzformen
EP0362728B1 (de) Verfahren zur Gewinnung von Ibuprofen für die Direkttablettierung
DE69219703T2 (de) Verfahren zum Trocknen und Granulieren von Aspartame
DE69122780T2 (de) Benzenedimethanolderivat geeignet für mikronisierung
DE3882466T2 (de) Neue Form des Riboflavins.
EP0126999B1 (de) Verfahren zur Herstellung von sphärisch-kristallinem 5-(Hydroxy)-tetracyclinhydrochlorid (Oxytetracyclinhydrochlorid)
DE3781095T2 (de) Calciumhypochloritzusammensetzungen und verfahren zu ihrer herstellung.
DE2949216C2 (de) Verfahren zur Herstellung von wasserfreier stabiler Lactose
DE4235133A1 (de) Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE69734460T2 (de) Verfahren zur kristallisierung eines tetrahydropyridinderivates und die so erhaltenen kristallinen formen
EP0362731A2 (de) Verfahren zur Herstellung von Arzneimittelwirkstoff-Partikeln mit verbesserten Fliess-, Lager- und Formulierungseigenschaften sowie Arzneimittel, die diese Arzneimittelwirkstoff-Partikeln enthalten
AT221501B (de) Verfahren zur Herstellung der neuen 4-Chlor-3-sulfamyl-benzoesäure und deren Alkalisalze
CH646730A5 (en) Process for the preparation of anhydrous stable lactose
DD276031A5 (de) Verfahren zur herstellung einer hartgelantinekapsel-zusammensetzung eines kristallinen hydrats der 7beta-[(z)-2-(2-aminothiazol-4-yl-)-4-carboxybut-2-enoylamino]-3-cephem-4-carbonsaeure
NO179248B (no) Fysikalsk form av N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetylÅ-3-metoksybenzoylÅ-2-metylbenzensulfonamid og fremgangsmåte for fremstilling derav

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB